Hemogenyx, Nitto Begin Feasibility Study on In Vivo CAR-T
The study will evaluate targeted LNP delivery of Hemogenyx’s FLT3-CAR mRNA to T cells, exploring an off-the-shelf in vivo CAR-T approach alongside its ongoing HG-CT-1 autologous program.
The study will evaluate targeted LNP delivery of Hemogenyx’s FLT3-CAR mRNA to T cells, exploring an off-the-shelf in vivo CAR-T approach alongside its ongoing HG-CT-1 autologous program.